Hospital health care resource utilization and costs of colorectal cancer during the first 3-year period following diagnosis in Switzerland

Alimentary Pharmacology and Therapeutics

Volumn 21, Issue 5, 2005, Pages 615-622

  Delco F ^a,c   Egger, R ^a   Bauerfeind, P ^b   Beglinger, C ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; COLONOSCOPY; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DATA BASE; ECHOGRAPHY; FEMALE; HEALTH CARE UTILIZATION; HOSPITAL CARE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SWITZERLAND; UNIVERSITY HOSPITAL;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; FEMALE; HEALTH RESOURCES; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; SWITZERLAND;

EID: 15044363918     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2005.02362.x     Document Type: Article

References (28)

1. American Cancer Society. Cancer Facts and Figures 2002. http://www.cancer.org/downloads/STT/CancerFacts&Figures 2002TM.pdf accessed on 27 December 2002. American Cancer Society, 2003.
2. International Agency for Research on Cancer. European Network of Cancer Registries, http://www-dep.iarc.fr/europe95/frame3.htm accessed on 27 December 2002. International Agency for Research on Cancer, 2002.
3. Kosary CL, Ries LAG, Miller BA, Hankey BF, Harras A, Edwards BK. (eds) SEER Cancer Statistics Review, 1973-1192: Tables and Graphs. Bethesda, MD: National Cancer Institute, NIH Pub. No. 96-2789, 1995.
4. Smith TJ, Hillner BE, Desch CE. Efficacy and cost-effectiveness of cancer treatment: rational allocation of resources based on decision analysis. J Natl Cancer Inst 1993; 85: 1460-74.
5. Schuette HL, Tucker TC, Brown ML, Potosky AL, Samuel T. The costs of cancer care in the United States: implications for action. Oncology (Huntingt) 1995; 9: 19-22.
6. Gold MR, Siegel JE, Russell LB, Weinstein M. Cost-effectiveness in Health and Medicine. New York, USA: Oxford University Press, 1996.
7. Die Spitäler der Schweiz. H+ Spitalstatistiken. Panoptikum: Medizinische Statistik 1996, administrative Statistik 1996: 27. Band. H+ Verlag: Aarau, 1997.
8. SPSS Inc. SPSS Version 11.5 US English for Windows. Chicago, USA: SPSS Inc., 2002.
9. Colon and rectum. American Joint Committee on Cancer: AJCC Cancer Staging Manual, 5th edn. Philadelphia, PA, USA: Lippincott-Raven Publishers, 1997: 83-90.
10. US National Cancer Institute, http://www.cancer.gov/cancerinfo/pdq/ treatment/colon/healthprofessional/ accessed on 21 December 2002.
11. US National Cancer Institute, http://www.cancer.gov/cancerinfo/pdq/ treatment/rectal/healthprofessional/ accessed on 21 December 2002.
12. Thomas RM, Sobin LH. Gastrointestinal cancer. Cancer (Suppl) 1995; 75: 154-70.
13. Ziegler RG, DeVesa SS, Fraumeni J. Epidemiologic pattern of colorectal cancer. In: Devita, VT, Hellmann, S, Rosenberg, SA, eds. Important Advances in Oncology. Philadelphia, PA, USA: JB Lippincott, 1986: 209.
14. Slattery ML, Friedman GD, Potter JD, Edwards S, Caan BJ, Samowitz W. A description of age, sex, and site distribution of colon carcinoma in three geographic areas. Cancer 1996; 78: 1666-70.
15. Hayne D, Brown RS, McCormack M, Quinn MJ, Payne HA, Babb P. Current trends in colorectal cancer: site, incidence, mortality, and survival in England and Wales. Clin Oncol (R Coll Radiol) 2001; 13: 448-52.
16. Sprangers MAG, Taal BG, Velde te A. Quality of life in colorectal cancer. Stoma vs nonstoma patients. Dis Colon Rect 1995; 38: 361-9.
17. Schag CAC, Ganz PA, Wing DS, Sim M-S, Lee JJ. Quality of life in adult survivors of lung, colon and prostate cancer. Qual Life Res 1994; 3: 127-41.
18. Forsberg C, Cedermark B. Well-being, general health and coping ability: 1-year follow-up of patients treated for colorectal and gastric cancer. Eur J Cancer Care 1996; 5: 209-16.
19. Rougier P, Van Cutsem E, Bajetta E, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352: 1407-12.
20. Cunninghan D, Pyrhönen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352: 1413-8.
21. Bleiberg H, de Gramont A. Oxaliplatin plus 5-fluorouracil: clinical experience in patients with advanced colorectal cancer. Semin Oncol 1998; 25 (2 Suppl. 5): 32-9.
22. Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18: 136-47.
23. US National Cancer Institute, http://www.cancer.gov/clinicaltrials/ results/irinotecan-plus0900 accessed on 21 December 2002.
24. Geddes M, Carli S, Ercolanelli M, Forno G, Capelli M, Barchielli A. Colorectal, lung, and breast cancer care during the three years following the diagnosis: a population-based study. Tumori 1996; 82: 210-4.
25. Riley GF, Potosky AL, Lubitz JD, Kessler LG. Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis. Med Care 1995; 33: 828-41.
26. Brown ML, Riley GF, Potosky AL, Etzioni RD. Obtaining long-term disease specific costs of care: application to Medicare enrollees diagnosed with colorectal cancer. Med Care 1999; 37: 1249-59.
27. Fireman BH, Quesenberry CP, Somkin CP, et al. Cost of care for cancer in a health maintenance organization. Health Care Finance Rev 1997; 18: 51-9.
28. O'Brien BD, Brown MG, Kephart G. Estimation of hospital costs for colorectal cancer care in Nova Scotia. Can J Gastroenterol 2001; 15: 143-7.